文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

炎症性肠病中抗TNF-α药物的治疗药物监测:局限与改进

Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements.
PubMed 文献 · Br J Clin Pharmacol · 2020-12-07

该综述检索PubMed和Cochrane Central,评估炎症性肠病中抗TNF-α药物治疗药物监测策略及个体化给药方法。共发现263篇TDM相关文献,仅7篇涉及主动TDM,其中5篇直接比较主动与被动TDM,2篇为随机临床试验。个体化给药方面发现229条结果,群体药代动力学是最常用的建模方法,但临床个体化 dosing 应用有限。

要点

  • 主动TDM呈增长趋势,与更长的治疗应答持续时间、更低的停药率和复发率相关。
  • 现有主动TDM证据有限且质量较低,尚无足够证据推荐主动TDM优于被动TDM。
  • 群体药代动力学常用于分析白蛋白浓度、体重、抗药抗体等因素对药物浓度的影响。

核心结论

  • 自2017年美国胃肠病学会推荐发布以来,炎症性肠病生物制剂监测推荐无重大变化。
  • 主动TDM呈增长趋势,与更长的治疗应答持续时间、更低的停药率和复发率相关,但证据有限且质量较低。
  • 群体药代动力学方法虽常用于分析药代动力学因素,但并未普遍用于个体化给药。

研究设计与样本

  • 综述类研究,检索PubMed和Cochrane Central,TDM策略部分检索2017年8月以后的文献。
  • 共发现263篇TDM相关出版物,其中仅7篇涉及主动TDM。
  • 7篇主动TDM文献中,5篇直接比较主动TDM与被动TDM,2篇为随机临床试验。
  • 个体化给药方法部分检索到229条不同结果。

主要发现

  • 5篇直接比较主动与被动TDM的研究中,6项研究发现主动TDM获益,1项发现无差异。
  • 群体药代动力学是开发个体剂量模型和分析因素对药物浓度影响最广泛使用的方法。
  • 分析的因素包括白蛋白浓度、体重、抗药抗体存在等。

临床怎么用

  • 临床可关注主动TDM策略,因其与更长的治疗应答持续时间、更低的停药率和复发率相关。
  • 群体药代动力学模型可用于分析白蛋白浓度、体重、抗药抗体等因素对药物浓度的影响。
  • 鉴于现有证据有限且质量较低,主动TDM优于被动TDM的推荐尚不充分。

局限性

  • 缺乏足够证据推荐主动TDM优于被动TDM。
  • 关于个体化给药方法的信息有限。
  • 现有主动TDM证据有限且质量较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Since the publication of the American Gastroenterological Association's recommendations in 2017, there have been no significant changes in the biological monitoring recommendations in inflammatory bowel disease. Possible limitations are the lack of evidence to recommend proactive therapeutic drug monitoring (pTDM) over reactive TDM (rTDM), and the limited information about individualized dosing methods. This article aims to review the TDM strategy updates and the use of individualized dosing methods. METHODS: For the analysis of the TDM strategies and individualized dosing method, a search was carried out in PubMed and Cochrane Central. In the TDM case, since August 2017. RESULTS: A total of 263 publications were found, but only 7 related to proactive TDM. Five of these publications directly compared pTDM vs rTDM and 2 were randomized clinical trials. Six studies found benefits of pTDM and 1 found no differences. Regarding the individualized dosing method, 229 distinct results were found. Population pharmacokinetics was the most widely used method to develop individual dosage models and to analyse the influence of factors on drug concentrations (albumin concentration, weight, presence of anti-drug antibodies etc). CONCLUSION: We have found no major changes in TDM strategies. There is a growing trend towards the use of pTDM because it has shown a longer duration of treatment response, lower rates of discontinuation and relapses. However, the available evidence is limited and of low quality. Despite the common use of population pharmacokinetic methods to analyse pharmacokinetic factors, they are not commonly used for personalized dosing.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Giráldez-Montero JM, Gonzalez-Lopez J, Campos-Toimil M, et al. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements. Br J Clin Pharmacol. 2020. PMID: 33197071. doi:10.1111/bcp.14654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。